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To the Editor,
Familial hypercholesterolemia (FH) is a genetically het-
erogeneous lipid disorder with a frequency of 1:300/1:500 
for heterozygotes in many populations [1]. The pathogen-
esis of FH is caused by a dysfunctional lipid metabolism 
leading to high concentrations of total and low-density 
lipoprotein (LDL) cholesterol, however, a great pheno-
typic variability is observed.
Mutations in the LDL receptor gene (LDLR) are the 
main cause of FH, whereas the apolipoprotein B (APOB) 
and proprotein convertase subtilisin/kexin type 9 (PCSK9) 
genes are involved in a lower percentage of cases [2]. 
PCSK9 regulates the LDLR expression inducing its lysoso-
mal degradation [3]. Some variants in PCSK9 increase its 
capacity to promote LDLR degradation [gain of function 
mutations (GOF)] leading to FH, whereas other mutations 
cause a decreased PCSK9 activity [loss of function (LOF)] 
[3]. The molecular diagnosis of FH implies that a new 
mutation should be deeply studied and accompanied by 
a functional characterization before one can claim its 
pathogenicity. Herein, we present the rare case of a family 
with a suspect of FH in which two members carried a new 
variant in the PCSK9 gene and two members carried a 
known variant in the APOB gene.
The proband (I.2; Figure 1) is a 68-year-old woman 
with hypercholesterolemia, hypertriglyceridemia as well 
as a clinical history of hypertension, hyperglycemia, 
carotid and peripheral atherosclerosis referred to the 
Dipartimento di Medicina Clinica e Chirurgia, Università 
degli Studi di Napoli Federico II. The study was performed 
according to the current version of the Helsinki Declara-
tion. Informed consent was obtained for each patient or 
control. The proband’s father died of a heart attack at the 
age of 64 and her mother has 7.8 mmol/L of total choles-
terol. The patient reported that she suspended previous 
therapies with atorvastatin or rosuvastatin due to the 
appearance of myalgia. Laboratory analyses in absence 
of therapy revealed an altered lipid profile as shown in 
Table 1. The proband (I.2) showed elevated serum levels 
of total cholesterol, LDL-cholesterol, triglycerides as well 
as increased apoB levels and LDL score. No sign of corneal 
arcus or tendinous xanthomata was found, leading to a 
diagnosis of possible FH according to the Simon Broome 
criteria [5]. Sequencing and MLPA analysis of the LDLR 
gene performed as previously described [6] did not reveal 
any mutation or large rearrangements in the proband. 
Sequencing of the 12 exons with flanking intron sequences 
of the PCSK9 gene showed that the proband (I.2) (Figure 1) 
was heterozygous for the new variant c.1394C > T in exon 9, 
corresponding to the amino acid substitution p.Ser465Leu.
We verified the absence of the variant in 150 chro-
mosomes from normocholesterolemic individuals. To 
evaluate the segregation of the new variant with the 
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hypercholesterolemic phenotype, the mutation was 
searched in the proband’s daughters (II.1 and II.2; Figure 1) 
aged 43 and 36 who showed elevated total cholesterol and 
LDL-cholesterol levels only partially corrected by a low 
fat diet (Table 1) without corneal arcus or tendinous xan-
thomata. The variant p.Ser465Leu was also identified in 
one of the proband’s daughters (II.2).
To predict the effects of the substitutions we used 
four different in silico algorithms suggesting that the 
p.Ser465Leu variant could affect the functionality of the 
protein: Polyphen (http://genetics.bwh.harvard.edu/
pph2) returns the result Probably damaging (score 1.00 
at Hum Div and 0.045 at HumVar); SIFT (http://sift.jcvi.
org): Not tolerated (score 0.02); Mutation taster (http://
www.mutationtaster.org): Disease causing (score 3.95); 
PMut (http://mmb.pcb.ub.es/): Pathological. BLASTP 
analysis confirmed that the amino acid residue involved 
in the substitution is conserved in 15/16 species. These 
algorithms cannot predict the GOF or LOF effect and it has 
been reported that predictions of GOF mutations should 
be interpreted with caution [7]. To assess the effects of the 
variant, two assays were performed to quantify the resid-
ual LDLR activity and the LDLR amount on the surface 
of patient’s cells as an indirect evaluation of the PCSK9 
effect. In fact, PCSK9 is secreted into the plasma and 
binds directly to LDLR on the cell surface; then, following 
endocytosis, it triggers LDLR degradation [3].
Peripheral blood mononuclear cells were isolated 
from patients and controls and incubated for 48  h in a 
medium with lipoprotein deficient serum (in order to up-
regulate LDLR) supplemented with ionomycin plus PMA 
to stimulate T-lymphocytes. Residual activity of LDLR 
was evaluated by measuring the binding and uptake of 
a fluorescently labeled LDL (1,19-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate-conjugated 
LDL, Life Technology, Foster City, CA, USA), namely DiI-
LDL, incubated with the cells for 3 h at 37 °C as previously 
described [8]. Amount of LDLR protein on the cell surface 
was evaluated by measuring the binding of an anti-LDLR 
antibody (Progen Biotechnik, Heidelberg, Germany) on 
stimulated T-lymphocytes. Cells were collected and incu-
bated at 4 °C for 1 h with the primary antibody diluted 1:20 
followed by an incubation at 4 °C for 45 min with the second-
ary FITC conjugated anti-rabbit antibody (BD Biosciences 
San Jose, CA, USA) diluted 1:200. Fluorescence intensities 
were measured with the FACSCanto (Becton-Dickinson, 
Table 1 Serum lipid profile of the patients.
  I.1a   Proband (I.2)a  II.1a   II.2a   Proband (I.2)b  II.1c   II.2c
Total cholesterol, mmol/L  4.2   11.6   6.5   6.2   4.8   5.7   5.9
LDL-cholesterol, mmol/L   2.5   8.4   4.3   4.6   2.3   3.7   4.1
HDL-cholesterol, mmol/L   1.1   1.5   1.4   1.4   1.3   1.5   1.5
Triglycerides, mmol/L   1.2   3.7   1.6   0.6   2.6   1.1   0.5
ApoB, g/L   0.81   1.97   not available  not available  0.9   1.00   1.00
LDL score (sdLDLd/LDL)   not available  37.1%   not available  not available  not available   4.2%   3.9%
aValues in absence of therapy; bValues after 3 years of therapy with simvastatin plus ezetimibe; cValues during a low fat diet; dsdLDL, small 








Median of fluorescence intensity (DiI-LDL)=122
Residual LDLR activity=42%
Median of fluorescence intensity (antibody)=2008
LDLR amounts on cell surface=122%
Median of fluorescence intensity (DiI-LDL)=173
Residual LDLR activity=60%
Median of fluorescence intensity (antibody)=1633
LDLR amounts on cell surface=99%
Figure 1 Pedigree of the FH family.
The proband is indicated by an arrow. White and gray symbols indicate heterozygosity for PCSK9 mutation p.Ser465Leu. Heterozygosity for 
p.Arg3558Cys mutation in APOB is indicated by symbols in black and white. Residual LDLR activities were calculated based on a mean of 
median fluorescence intensities of the cells from two controls equal to 287; the LDLR amounts were calculated based on a mean of median 
fluorescence intensities of the cells from two controls obtained with anti-LDLR antibody equal to 1643.
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Franklin Lakes, NJ, USA) flow cytometer. LDLR activity or 
amount of LDLR protein on the cell surface was calculated 
as the ratio between the median fluorescence intensity of 
the patients’ cells and the mean of median fluorescence 
intensities of the cells from two controls.
LDLR residual activity in the proband (I.2) and her 
daughter (II.2) who both bore the c.1394C > T variant, was 
42% and 60%, whereas the amounts of LDLR protein on 
the cell surface were 122% and 99%, respectively (Figure 1).
The decreased LDLR activity observed in both the 
proband and her daughter (42% and 60%, respectively) 
together with a small increase or normal LDLR amounts 
could indicate the dysfunction in LDLR endocytosis as 
the cause of increased levels of LDL cholesterol in both 
the mother and the daughter. Our results do not support 
a pathological role of the new PCSK9 variant, although it 
cannot be ruled out because a defect in endocytic pathway 
could mask its effect, since endocytosis is required for its 
action as recently described [9]. In addition, other mecha-
nisms of PCSK9 action unrelated to LDR can be responsi-
ble for increased cholesterol levels [10].
Furthermore, since the proband’s daughter II.1 showed 
hypercholesterolemia without mutations in PCSK9, the 
genetic screening was extended to the LDLR and to all the 
29 exons with intron-exon boundaries of APOB gene. A 
mutation in exon 26 of the APOB gene (c.10672C > T/p.Arg-
3558Cys) was identified in this patient and successively in 
her father (I.1) who showed a normolipidemic profile.
The p.Arg3558Cys mutation in the APOB gene was 
previously described as pathogenic for FH and associated 
with a decreased receptor binding affinity of LDL ranging 
from 30% to 70% and with a high variability of total cho-
lesterol levels ranging from 4.2  mmol/L to 10.9  mmol/L 
[11]. The above findings are supported by our observa-
tions, since p.Arg3558Cys mutation is associated with a 
normal lipid profile in the patient I.1, but at the same time 
it is associated with a mild hyperlipidemic profile in the 
patient II.1.
In conclusion, the new variant p.Ser465Leu in PCSK9 
is not associated to a decreased LDLR amount on the cell 
membrane and does not explain the reduced LDL activity 
which is the cause of the FH phenotype. This case report 
highlights the importance of a deep study of genetic vari-
ants before claiming their pathogenicity.
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